GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (OTCPK:ORGS) » Definitions » Cyclically Adjusted PB Ratio

ORGS (Orgenesis) Cyclically Adjusted PB Ratio : 0.15 (As of May. 12, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Orgenesis Cyclically Adjusted PB Ratio?

As of today (2025-05-12), Orgenesis's current share price is $1.985. Orgenesis's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was $13.30. Orgenesis's Cyclically Adjusted PB Ratio for today is 0.15.

The historical rank and industry rank for Orgenesis's Cyclically Adjusted PB Ratio or its related term are showing as below:

ORGS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 3.38   Max: 31.81
Current: 0.14

During the past years, Orgenesis's highest Cyclically Adjusted PB Ratio was 31.81. The lowest was 0.08. And the median was 3.38.

ORGS's Cyclically Adjusted PB Ratio is ranked better than
83.01% of 665 companies
in the Biotechnology industry
Industry Median: 1.47 vs ORGS: 0.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Orgenesis's adjusted book value per share data for the three months ended in Sep. 2024 was $-5.009. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $13.30 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Orgenesis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Cyclically Adjusted PB Ratio Chart

Orgenesis Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.34 6.16 2.94 1.67 0.39

Orgenesis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.39 0.63 0.46 0.34

Competitive Comparison of Orgenesis's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted PB Ratio falls into.


;
;

Orgenesis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Orgenesis's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.985/13.30
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Orgenesis's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-5.009/133.0289*133.0289
=-5.009

Current CPI (Sep. 2024) = 133.0289.

Orgenesis Quarterly Data

Book Value per Share CPI Adj_Book
201411 -6.393 99.635 -8.536
201502 -7.775 99.032 -10.444
201505 -10.833 100.333 -14.363
201508 -12.817 100.548 -16.957
201511 -13.849 100.135 -18.398
201602 18.413 100.040 24.485
201605 16.822 101.355 22.079
201608 14.941 101.617 19.560
201611 13.141 101.829 17.167
201702 5.880 102.779 7.611
201705 9.978 103.256 12.855
201708 11.446 103.587 14.699
201711 14.309 104.072 18.290
201802 18.966 105.052 24.017
201805 19.399 106.148 24.312
201808 21.751 106.383 27.199
201811 18.963 106.338 23.723
201903 12.896 107.251 15.996
201906 9.997 108.070 12.306
201909 6.485 108.329 7.964
201912 3.393 108.420 4.163
202003 48.755 108.902 59.557
202006 39.943 108.767 48.853
202009 39.230 109.815 47.523
202012 21.709 109.897 26.279
202103 22.347 111.754 26.601
202106 20.930 114.631 24.289
202109 17.570 115.734 20.196
202112 15.852 117.630 17.927
202203 13.981 121.301 15.333
202206 12.793 125.017 13.613
202209 11.825 125.227 12.562
202212 10.787 125.222 11.460
202303 9.931 127.348 10.374
202306 8.418 128.729 8.699
202309 4.069 129.860 4.168
202312 -6.582 129.419 -6.766
202403 -8.071 131.776 -8.148
202406 -3.302 132.554 -3.314
202409 -5.009 133.029 -5.009

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis  (OTCPK:ORGS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Orgenesis Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Orgenesis's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Orgenesis Business Description

Industry
Traded in Other Exchanges
N/A
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.
Executives
Jacob Safier 10 percent owner C/O THE WOLFSON GROUP, ONE STATE STREET PLAZA 29TH FLOOR, NEW YORK NY 10004
Elliot Maltz officer: Chief Financial Officer C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Efrat Assa Kunik officer: Chief Development Officer C/O ORGENESIS INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Mario Philips director C/O ATMI, INC, DANBURY CT 06810
Sarah Ferber officer: Chief Scientific Officer 17B HAHASKALA STREET, TEL AVIV L3 67890
Guy Yachin director 7 ORCHARD WAY N, POTOMAC MD 20854
Yaron Adler director 4 HA'NECHOSHET ST., RAMAT HA'CHAYAL, TEL AVIV L3 69710
Vered Caplan officer: CEO 20 HA'ETZEL STREET, PO BOX 9118 RAMAT EFAL, KIRYAT ONO L3 55280
Universite Libre De Bruxelles 10 percent owner AVENUE F, ROOSEVELT, 50, BRUSSELS C9 1050
Olivier Belenger 10 percent owner DIEWEG, 69, BRUSSELS C9 1070
Ii Sa Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Sca Theodorus 10 percent owner ALLEE DE LA RECHERCHE, 12, BRUSSELS C9 1070
Denis Bedoret officer: See Remarks 48, RUE AUGUSTE PICCARD, GOSSELIES C9 6041
Ashish Nanda director 2301, 23RD FLOOR, TIFFANY TOWERS, CLUSTER W, JLT, DUBAI, UAE, DUBAI C0 4452